Institute of Organic and Macromolecular Chemistry, Heinrich-Heine University Düsseldorf, Universitätsstraße 1, Düsseldorf, 40225, Germany.
Laboratory for Biomaterials, Institute for Biotechnology and Helmholtz-Institute for Biomedical Engineering, RWTH Aachen University, Pauwelsstr. 20, Aachen, 52074, Germany.
Macromol Biosci. 2020 Sep;20(9):e2000163. doi: 10.1002/mabi.202000163. Epub 2020 Jul 26.
Within this work, a new class of sequence-defined heteromultivalent glycomacromolecules bearing lactose residues and nonglycosidic motifs for probing glycoconjugate recognition in carbohydrate recognition domain (CRD) of galectin-3 is presented. Galectins, a family of β-galactoside-binding proteins, are known to play crucial roles in different signaling pathways involved in tumor biology. Thus, research has focused on the design and synthesis of galectin-targeting ligands for use as diagnostic markers or potential therapeutics. Heteromultivalent precision glycomacromolecules have the potential to serve as ligands for galectins. In this work, multivalency and the introduction of nonglycosidic motifs bearing either neutral, amine, or sulfonated/sulfated groups are used to better understand binding in the galectin-3 CRD. Enzyme-linked immunosorbent assays and surface plasmon resonance studies are performed, revealing a positive impact of the sulfonated/sulfated nonglycosidic motifs on galectin-3 binding but not on galectin-1 binding. Selected compounds are then tested with galectin-3 positive MCF 7 breast cancer cells using an in vitro would scratch assay. Preliminary results demonstrate a differential biological effect on MCF 7 cells with high galectin-3 expression in comparison to an HEK 293 control with low galectin-3 expression, indicating the potential for sulfonated/sulfated heteromultivalent glycomacromolecules to serve as preferential ligands for galectin-3 targeting.
在这项工作中,我们提出了一类新的序列定义的杂合多价糖基大分子,它们带有乳糖残基和非糖基结构域,用于探测半乳糖凝集素-3(Galectin-3)中糖缀合物识别的碳水化合物识别结构域(CRD)。半乳糖凝集素是一类β-半乳糖苷结合蛋白,已知在涉及肿瘤生物学的不同信号通路中发挥关键作用。因此,研究集中在设计和合成针对半乳糖凝集素的靶向配体,用作诊断标志物或潜在的治疗药物。杂合多价精确糖基大分子有可能作为半乳糖凝集素的配体。在这项工作中,我们使用多价性和引入带有中性、胺基或磺化/硫酸化基团的非糖基结构域来更好地理解半乳糖凝集素-3 CRD 中的结合。进行了酶联免疫吸附测定和表面等离子体共振研究,结果表明磺化/硫酸化非糖基结构域对半乳糖凝集素-3 的结合有积极影响,但对半乳糖凝集素-1 的结合没有影响。然后,用半乳糖凝集素-3 阳性 MCF 7 乳腺癌细胞和体外划痕试验对选定的化合物进行测试。初步结果表明,与低半乳糖凝集素-3 表达的 HEK 293 对照相比,高半乳糖凝集素-3 表达的 MCF 7 细胞具有不同的生物学效应,表明磺化/硫酸化杂合多价糖基大分子有可能作为半乳糖凝集素-3 靶向的优先配体。